Dr. Jing Zhang specializes in clinical and quantitative pharmacology, and have established a clinical pharmacology research platform for antibacterial agents. As a principal investigator, she has completed over 200 clinical pharmacology studies, including first-in-human trials, pharmacokinetic evaluations in special populations and patients, and bioequivalence assessments. She has also applied population pharmacokinetics and PK/PD modeling to the full-lifecycle evaluation of antibacterial drugs. She has led two GCP projects under the Major New Drug Development Program of the Ministry of Science and Technology, one project under the National Key Research and Development Program and two National Natural Science Foundation of China (NSFC) projects and one cooperative project with scholars from overseas, Hong Kong, Macao and Taiwan. As a key participant, she has completed over ten provincial and ministerial-level projects. As the course leader, she is responsible for undergraduate and postgraduate courses related to drug clinical research at Fudan University. She has served as the chief editor and participated in the compilation of 13 monographs and textbooks, including “Pharmacokinetics – Pharmacodynamics: Theory and Application”, ” Drug Clinical Research: Theory and Practice”, and “Practical Internal Medicine”, and has been granted 5 patents. In the past decade, she has published over 200 papers as the first or corresponding author in domestic and international journals and have trained nearly 50 master’s and doctoral students. She has participated in the drafting and formulation of dozens of series of guiding principles for clinical trials of antibacterial drugs and related guiding principles in clinical pharmacology, making significant contributions to the early clinical research and the construction of the drug evaluation system in China. As the first contributor, she has won over ten awards including the First Prize of Shanghai Science and Technology Progress Award, the First Prize of Shanghai Pharmaceutical Association Science and Technology Award, and the Second Prize of China Pharmaceutical Science and Technology Award. She has also been honored as a Leading Talent of Shanghai, a Leading figure of Shanghai Women’s Innovation, and a March 8th Red Flag Bearer of Shanghai Health and Wellness System.
张菁博士
特聘教授
复旦大学附属华山医院主任药师、教授
External Honorary Professor
Chief Pharmacist, Professor, Huashan Hospital affiliated to Fudan University
张菁博士专长临床药理及定量药理研究，建立抗菌药物临床药理学研究平台，作为PI完成200余项临床药理学研究，涵盖首次人体试验、特殊人群及患者的药代动力学研究、生物等效性评价等，并将群体药动学、药动学/药效学建模应用于抗菌药物的全生命周期评估。牵头科技部重大新药创制专项GCP课题2项以及国家重点研发计划1项，主持国家自然基金项目2项和海外及港澳台学者合作项目1项，作为主要参加者完成了省部级课题10余项。作为课程负责人，承担复旦大学药物临床研究相关的本科及研究生课程。主编及参与编写《药动学-药效学：理论与应用》《药物临床研究：理论与实践》《实用内科学》等专著和教材13部，获授权专利5项。近十年以第一或通讯作者身份在国内外杂志发表论文200余篇，培养硕士和博士生近50名。参与几十项抗菌药临床试验系列指导原则以及临床药理学相关指导原则的起草及制定，协助推进我国早期临床研究和药物评价体系建设。作为第一完成人获上海市科技进步一等奖、上海市药学会科技一等奖和中国药学科技二等奖等10余项奖励，荣获上海市领军人才、上海市巾帼创新领军人物和上海市卫生健康系统三八红旗手。
Dr. Jing Zhang specializes in clinical and quantitative pharmacology, and have established a clinical pharmacology research platform for antibacterial agents. As a principal investigator, she has completed over 200 clinical pharmacology studies, including first-in-human trials, pharmacokinetic evaluations in special populations and patients, and bioequivalence assessments. She has also applied population pharmacokinetics and PK/PD modeling to the full-lifecycle evaluation of antibacterial drugs. She has led two GCP projects under the Major New Drug Development Program of the Ministry of Science and Technology, one project under the National Key Research and Development Program and two National Natural Science Foundation of China (NSFC) projects and one cooperative project with scholars from overseas, Hong Kong, Macao and Taiwan. As a key participant, she has completed over ten provincial and ministerial-level projects. As the course leader, she is responsible for undergraduate and postgraduate courses related to drug clinical research at Fudan University. She has served as the chief editor and participated in the compilation of 13 monographs and textbooks, including “Pharmacokinetics – Pharmacodynamics: Theory and Application”, ” Drug Clinical Research: Theory and Practice”, and “Practical Internal Medicine”, and has been granted 5 patents. In the past decade, she has published over 200 papers as the first or corresponding author in domestic and international journals and have trained nearly 50 master’s and doctoral students. She has participated in the drafting and formulation of dozens of series of guiding principles for clinical trials of antibacterial drugs and related guiding principles in clinical pharmacology, making significant contributions to the early clinical research and the construction of the drug evaluation system in China. As the first contributor, she has won over ten awards including the First Prize of Shanghai Science and Technology Progress Award, the First Prize of Shanghai Pharmaceutical Association Science and Technology Award, and the Second Prize of China Pharmaceutical Science and Technology Award. She has also been honored as a Leading Talent of Shanghai, a Leading figure of Shanghai Women’s Innovation, and a March 8th Red Flag Bearer of Shanghai Health and Wellness System.